Related Experiment Videos
Controlled trials of a polyvalent pseudomonas vaccine in burns
Insights
A polyvalent Pseudomonas vaccine significantly reduced Pseudomonas aeruginosa infections and mortality in burn patients. Vaccinated individuals showed increased protective antibodies and phagocytic activity against the bacteria.
Area of Science:
- Immunology
- Infectious Diseases
- Burn Care
Background:
- Pseudomonas aeruginosa is a common and dangerous pathogen in burn wound infections.
- High mortality rates from Pseudomonas aeruginosa infections are prevalent in burn units, particularly in regions like New Delhi.
Purpose of the Study:
- To evaluate the efficacy of a polyvalent Pseudomonas vaccine in preventing Pseudomonas aeruginosa infections in burn patients.
- To assess the impact of the vaccine on mortality rates associated with Pseudomonas aeruginosa infections in clinical settings.
Main Methods:
- Controlled clinical trials were conducted in two burns units (Birmingham and New Delhi).
- The study included children and adults with burns exceeding 15% of full skin thickness.
- Vaccinated and unvaccinated groups were compared for Pseudomonas aeruginosa blood culture results, antibody titers, phagocytic activity, and mortality.
Main Results:
- No vaccinated patients in either trial had Pseudomonas aeruginosa in their blood cultures.
- Vaccinees demonstrated elevated titers of protective antibodies and increased phagocytic activity against Pseudomonas aeruginosa.
- In New Delhi, adult mortality decreased from 40.6% to 6.6%, and child mortality decreased from 20.8% to 4.8% in vaccinated groups.
Conclusions:
- The polyvalent Pseudomonas vaccine is effective in preventing Pseudomonas aeruginosa bloodstream infections in burn patients.
- Vaccination with the polyvalent Pseudomonas vaccine significantly reduces mortality rates in burn patients suffering from Pseudomonas aeruginosa infections.
- The vaccine induces a measurable immune response, including increased protective antibody levels and enhanced phagocytic activity.
Abstract:
A polyvalent pseudomonas vaccine has been tested in controlled clinical trials at two burns units, in Birmingham and New Delhi, in children and adults with burns more than 15% full skin thickness. None of the vaccinated patients in either trial showed blood cultures containing Pseudomonas aeruginosa, and vaccinees showed raised titres of protective antibody and increased phagocytic activity against Ps. aeruginosa. In the New Delhi unit, where death from Ps. aeruginosa infection is common, the mortality in adults was reduced from 40.6% (13/32) in the unvaccinated group to 6.6% (2/30) in the vaccinated group, and in children from 20.8% (5/24) in the unvaccinated group to 4.8% (1/21) in the vaccinated group.